Consensus Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Real-time Estimate Cboe BZX Other stock markets 12:10:26 2024-05-06 EDT			5-day change	1st Jan Change
27.65 ^USD	-2.47%		+2.65%	+173.21%

04-29	Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	MT
04-29	Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer	CI

Evolution of the average Target Price on Cullinan Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

302ab72a97f6f819eafaaf721e4.ug5gHMefZFbrnAYp86or3FX15cKySNBSsrO8mrCp4vg.8T8ISYutAjqN-EpOpescpGStgoqKfOEwgYbmyuTnt4KPNi8uhNQXD4b3ZQ~cc3ce2f1bb82b9190cdc9524de387ad7

Analyst Recommendations on Cullinan Therapeutics, Inc.

CULLINAN ONCOLOGY : Morgan Stanley Adjusts Cullinan Oncology's Price Target to $43 From $40, Maintains Overweight Rating	21-06-07	MT
CULLINAN ONCOLOGY : HC Wainwright Adjusts Cullinan Management PT to $55 From $48, Maintains Buy Rating	21-06-04	MT
CULLINAN ONCOLOGY : SVB Leerink Adjusts Price Target on Cullinan Management to $54 From $48, Maintains Outperform Rating	21-06-04	MT
CULLINAN ONCOLOGY : Morgan Stanley Upgrades Cullinan Management to Overweight from Equalweight, Sets $40 Price Target	21-04-27	MT
CULLINAN ONCOLOGY : Morgan Stanley Adjusts Price Target on Cullinan Management to $40 From $38, Maintains Equal-Weight Rating	21-04-19	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.35 USD

Average target price

33.12 USD

Spread / Average Target

+16.84%

High Price Target

40 USD

Spread / Highest target

+41.09%

Low Price Target

28 USD

Spread / Lowest Target

-1.23%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cullinan Therapeutics, Inc.

Morgan Stanley
SVB Leerink
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar